Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab

NCT01871311 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT01871311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01871311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab
Lead sponsor
Georgetown University
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2014
Completion date
December 31, 2016
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, head and neck cancer